#USA #Boston #Morphic Medical #Joe Virgilio #Mike Gutteridge

Morphic Medical Leadership Transition

Morphic Medical, a trailblazer in MedTech specializing in minimally invasive treatments for obesity and cardiometabolic disorders, has made significant waves in the healthcare industry recently with the announcement of a leadership transition. After five impactful years at the helm, Joe Virgilio will be stepping down as the CEO of the company. Under his leadership, Morphic Medical achieved numerous milestones in product development, manufacturing enhancement, and organizational growth.

Notably, Virgilio's tenure included overseeing the regulatory approval of the innovative RESET® therapy in the European Union earlier this year, marking a significant achievement for the company dedicated to improving patient outcomes.

With this leadership change, the company is excited to welcome Mike Gutteridge as the new Chief Executive Officer. Gutteridge brings a wealth of experience in the field of bariatric endoscopy, having recently served as the Vice President of Therapy Development and Commercial Operations at Morphic. During his previous role, Gutteridge was instrumental in crafting the go-to-market strategy for the RESET® therapy.

Mark Lerdal, the Chair of the Board, expressed gratitude to Virgilio for his vision and contributions, stating, “Joe has played a crucial role in shaping Morphic Medical into what it is today. We are thankful for his leadership and commitment to innovation and patient care.” Lerdal also shared enthusiasm for Gutteridge, emphasizing his alignment with the company's values and experience in international commercialization, especially as Morphic enters its next growth phase.

Reflecting on his experiences, Virgilio said, “Leading Morphic Medical over the past five years has been a privilege. I am proud of what our fantastic team has accomplished, and I am confident in the future of the company under Mike's leadership. I remain committed to our mission and look forward to supporting Mike and the Board in transitioning Morphic into this exciting new chapter.”

In response to his new role, Gutteridge expressed his gratitude, stating, “I am honored to succeed Joe Virgilio as the CEO of Morphic Medical. With over 30 years of experience in the medical technology sector, covering clinical innovation, business strategy, market development, and reimbursement, I am eager to steer Morphic toward its next phase. This includes targeted global market expansion, accelerated commercialization, and an enhanced commitment to improve patients’ lives through effective and sustainable therapies.”

Gutteridge aims to build upon the groundbreaking work Morphic has done in the realm of gastro-intestinal metabolic health and continue fostering a culture of agility, purpose, and partnership. He emphasized the importance of teamwork across Morphic's exceptional staff, along with their growing network of clinicians, researchers, and investors, to ensure that Morphic technology reaches those who need it most while creating sustainable value through responsible growth.

As the company navigates this leadership transition, steps will be taken to ensure continuity in operations, stakeholder engagement, and partnerships. The future looks promising for Morphic Medical as it sets its sights on refining its strategies and furthering its commitment to health innovation.

About Morphic Medical

Founded in 2003 and based in Boston, Massachusetts, Morphic Medical focuses on the development of RESET, an endoscopic therapy that provides a non-surgical alternative for the treatment of severe obesity, particularly for individuals with concomitant cardiometabolic risk factors such as type 2 diabetes and dyslipidemia. In the United States, RESET is not available for sale and is limited to experimental use under federal law. For further information, visit morphicmedical.com or follow Morphic Medical on Twitter and LinkedIn.